truncated l1 hpv33 protein or variant thereof, isolated nucleic acid, vector, host cell, hpv33 viral type particle, composition, pharmaceutical composition or vaccine, method for obtaining a truncated l1 hpv33 protein, method for preparing the hpv33 viral particle, method for preparing a vaccine, method for preventing hpv infection or a disease caused by hpv infection, and use of truncated or variant l1 hpv33 protein

摘要

abstract “truncated l1 hpv33 protein or variant thereof, isolated nucleic acid, vector, host cell, hpv33 viral type particle, composition, pharmaceutical composition or vaccine, method for obtaining a truncated l1 hpv33 protein, method for preparing the viral type particle hpv33, method for preparing a vaccine, method for preventing hpv infection or a disease caused by hpv infection and use of truncated or variant hpv33 l1 protein The present invention relates to a truncated human papilloma virus l1 protein (hpv) type 33, a coding sequence thereof, a method for preparing it, and a viral type particle comprising the same, wherein the protein and viral type particle are useful for preventing hpv infection. (particularly hpv33), and a disease caused by hpv infection (particularly hpv33), such as cervical cancer. The invention also relates to the use of the viral-like protein and particle in the preparation of a pharmaceutical composition or a vaccine for preventing the invention by hpv (particularly hpv33), and a disease caused by hpv infection (particularly hpv33), such as cervical cancer. 1